|
HRKorea |
ÀÓ»ó°³¹ßÆÀ PMS ÆÄÆ®¿ø(1¸í) - IRB Á¦Ãâ¹®¼ ±¸ºñ ¹× ½ÉÀÇ
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
12.31 |
04.05 |
|
|
ÇÁ·ÎÇÚÁîÄÚ¸®¾Æ |
À¯¸í¹ÙÀÌ¿ÀÁ¦¾à»ç ÀÓ»óÆÀÀå(°úÂ÷Àå±Þ)
°æ±â ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
10³â¡è |
ä¿ë½Ã |
11.07 |
|
|
HRKorea |
Biometrics ´ã´çÀÚ Ã¤¿ë - ÀÓ»ó°³¹ß Àü·« ±âȹ, CRO °ü¸® °¨
¼¿ï ÀüÁö¿ª | ´ëÇпø(¼®»ç) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
3³â¡è |
07.31 |
11.07 |
|
|
HRKorea |
CPM (Clinical Project Manager) ´ã´çÀÚ Ã¤¿ë - ÀÓ»ó °³¹ß
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
3³â¡è |
07.31 |
11.07 |
|
|
HRKorea |
PV(Pharmacovigilance) ´ã´çÀÚ Ã¤¿ë - ÀÓ»ó½ÃÇè SAE Handlin
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
5³â¡è |
07.31 |
11.07 |
|
|
ÇÁ·ÎÇÚÁîÄÚ¸®¾Æ |
´ëÇüÁ¦¾à»ç ÀÓ»óPM(»ç¿ø~Â÷Àå±Þ) 2¸í
°æ±â ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
ä¿ë½Ã |
03.26 |
|
|
ÇÁ·ÎÇÚÁîÄÚ¸®¾Æ |
¿Ü±¹°èCRO DMA(3³âÀÌ»ó)
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
3³â¡è |
ä¿ë½Ã |
04.24 |
|
|
ÇÁ·ÎÇÚÁîÄÚ¸®¾Æ |
´ëÇüÁ¦¾à»ç PMS PM(ÆÄÆ®Àå-´ë¸®±ÞÀÌ»ó)1¸í/ÆÀ¿ø 2¸í(»ç¿ø~ÁÖ
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
ä¿ë½Ã |
09.28 |
|
|
ÇÁ·ÎÇÚÁîÄÚ¸®¾Æ |
Áß°ßÁ¦¾à»ç ÀÓ»ó PM(1~5³â)
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
ä¿ë½Ã |
08.23 |
|
|
±×·¹À̽º¾ØÆÄÆ®³Ê½º |
Àӻ󿬱¸ÆÀ
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
7³â¡è |
ä¿ë½Ã |
08.18 |
|
|
ÇÁ·ÎÇÚÁîÄÚ¸®¾Æ |
´ëÇüÁ¦¾à»ç CRÆÀÀå
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
10³â¡è |
ä¿ë½Ã |
10.10 |
|
|
ÇÁ·ÎÇÚÁîÄÚ¸®¾Æ |
´ëÇüÁ¦¾à»ç ÀÓ»ó°³¹ßÆÀ(»ç¿ø~´ë¸®±Þ)
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
ä¿ë½Ã |
08.10 |
|
|
ÇÁ·ÎÇÚÁîÄÚ¸®¾Æ |
»óÀåÁ¦¾à»ç ÀÓ»óÆÀ(7³âÀÌ»ó)
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
7³â¡è |
ä¿ë½Ã |
09.28 |
|
|
ÇÁ·ÎÇÚÁîÄÚ¸®¾Æ |
Áß°ßÁ¦¾à»ç ÀÓ»ó PM(1~5³â)
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
ä¿ë½Ã |
04.18 |
|
|
ÇÁ·ÎÇÚÁîÄÚ¸®¾Æ |
»óÀåÁ¦¾à»ç ÀÓ»ó°³¹ß(7³âÀÌ»ó)-ASAP
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
7³â¡è |
ä¿ë½Ã |
08.30 |
|